NYSE
130.90USD
+4.27 (+3.37%)
We have scored 10 news catalysts on Veradermics, Incorporated (MANE) over the past 12 months. The biggest single-day move next to one of them came Apr 27, 2026, when MANE closed +47.6%: “Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss Transcript”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.5B
P/E
—
EPS
—
Beta
1.23
52W range
32-136.72
Day range
123.02–135.12
Open
125.71
Prev close
126.63
Volume
1.1M
Avg volume
759.2K
Dividend
0.00
IPO
2026-02-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Veradermics, Incorporated — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for MANE: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
